35 research outputs found

    Validation of MIPAS-ENVISAT NO2 operational data

    Get PDF
    The Michelson Interferometer for Passive Atmospheric Sounding (MIPAS) instrument was launched aboard the environmental satellite ENVISAT into its sun-synchronous orbit on 1 March 2002. The short-lived species NO<sub>2</sub> is one of the key target products of MIPAS that are operationally retrieved from limb emission spectra measured in the stratosphere and mesosphere. Within the MIPAS validation activities, a large number of independent observations from balloons, satellites and ground-based stations have been compared to European Space Agency (ESA) version 4.61 operational NO<sub>2</sub> data comprising the time period from July 2002 until March 2004 where MIPAS measured with full spectral resolution. Comparisons between MIPAS and balloon-borne observations carried out in 2002 and 2003 in the Arctic, at mid-latitudes, and in the tropics show a very good agreement below 40 km altitude with a mean deviation of roughly 3%, virtually without any significant bias. The comparison to ACE satellite observations exhibits only a small negative bias of MIPAS which appears not to be significant. The independent satellite instruments HALOE, SAGE II, and POAM III confirm in common for the spring-summer time period a negative bias of MIPAS in the Arctic and a positive bias in the Antarctic middle and upper stratosphere exceeding frequently the combined systematic error limits. In contrast to the ESA operational processor, the IMK/IAA retrieval code allows accurate inference of NO<sub>2</sub> volume mixing ratios under consideration of all important non-LTE processes. Large differences between both retrieval results appear especially at higher altitudes, above about 50 to 55 km. These differences might be explained at least partly by non-LTE under polar winter conditions but not at mid-latitudes. Below this altitude region mean differences between both processors remain within 5% (during night) and up to 10% (during day) under undisturbed (September 2002) conditions and up to 40% under perturbed polar night conditions (February and March 2004). The intercomparison of ground-based NDACC observations shows no significant bias between the FTIR measurements in Kiruna (68&deg; N) and MIPAS in summer 2003 but larger deviations in autumn and winter. The mean deviation over the whole comparison period remains within 10%. A mean negative bias of 15% for MIPAS daytime and 8% for nighttime observations has been determined for UV-vis comparisons over Harestua (60&deg; N). Results of a pole-to-pole comparison of ground-based DOAS/UV-visible sunrise and MIPAS mid-morning column data has shown that the mean agreement in 2003 falls within the accuracy limit of the comparison method. Altogether, it can be indicated that MIPAS NO<sub>2</sub> profiles yield valuable information on the vertical distribution of NO<sub>2</sub> in the lower and middle stratosphere (below about 45 km) during day and night with an overall accuracy of about 10&ndash;20% and a precision of typically 5&ndash;15% such that the data are useful for scientific studies. In cases where extremely high NO<sub>2</sub> occurs in the mesosphere (polar winter) retrieval results in the lower and middle stratosphere are less accurate than under undisturbed atmospheric conditions

    GOMOS HIGH RESOLUTION TEMPERATURE VALIDATION BY THE MASI AND ESABC GROUPS

    No full text
    ABSTRACT/RESUME At the 2 nd Workshop of the Atmospheric Chemistry Validation of Envisat (ACVE-2), re-processed high resolution temperature data from GOMOS (GOPR_LV2/6.0a) were evaluated using independent satellite data. This paper presents results of the validation activities of Service d&apos;Aeronomie, CNRS, France, member of the MASI and ESABC validation subgroup of the Atmospheric Chemistry Validation Team (ACVT) for Envisat

    OVERVIEW ON VALIDATION OF MIPAS H 2 O VAPOUR BY COMPARISON WITH INDEPENDENT SATELLITE MEASUREMENTS

    No full text
    ABSTRACT The water vapour operational data products from MIPAS (V4.61) have been validated by comparison with independent satellite measurements from HALO

    Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review

    No full text
    International audienceAbemaciclib (Verzerio®) is a cell cycle inhibitor of both CDK4 and CDK6. In 2017, abemaciclib was approved by the Food and Drug Administration (FDA) and, in 2018 by the European Medicines Agency (EMA) for the treatment of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. In this mini-review, we provide a series of information for respectively their targets and its selectivity, results on preclinical trial, clinical phase I, II and III trials, and some perspectives. We also describe the batch and flow steps used for the synthesis of this cancer drug
    corecore